Safety analysis set | n (%) | |
---|---|---|
VEGF Trap-Eye 2Q4 (n=104) | Sham (n=68) | |
Any ocular SAE | 3 (2.9) | 6 (8.8) |
Glaucoma | 0 (0.0) | 2 (2.9) |
Macular oedema* | 0 (0.0) | 2 (2.9) |
Visual acuity reduced | 0 (0.0) | 1 (1.5) |
Vitreous haemorrhage | 0 (0.0) | 1 (1.5) |
Iris neovascularisation | 1 (1.0) | 0 (0.0) |
Macular ischaemia | 1 (1.0) | 0 (0.0) |
Vitreous detachment | 1 (1.0) | 0 (0.0) |
*Macular oedema could be reported as an adverse event, if worsening of macular oedema was observed.